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Background: Epitope identification is an essential step toward synthetic vaccine development since epitopes play
an important role in activating immune response. Classical experimental approaches are laborious and time-
consuming, and therefore computational methods for generating epitope candidates have been actively studied.
Most of these methods, however, are based on sophisticated nonlinear techniques for achieving higher predictive
performance. The use of these techniques tend to diminish their interpretability with respect to binding potential:
that is, they do not provide much insight into binding mechanisms.
Results: We have developed a novel epitope prediction method named EpicCapo and its variants, EpicCapo+
and EpicCapo+REF. Nonapeptides were encoded numerically using a novel peptide-encoding scheme for machine
learning algorithms by utilizing 40 amino acid pairwise contact potentials (referred to as AAPPs throughout this
paper). The predictive performances of EpicCapo+ and EpicCapo+REF outperformed other state-of-the-art methods
without losing interpretability. Interestingly, the most informative AAPPs estimated by our study were those
developed by Micheletti and Simons while previous studies utilized two AAPPs developed by Miyazawa & Jernigan
and Betancourt & Thirumalai. In addition, we found that all amino acid positions in nonapeptides could effect on
performances of the predictive models including non-anchor positions. Finally, EpicCapo+REF was applied to identify
candidates of promiscuous epitopes. As a result, 67.1% of the predicted nonapeptides epitopes were consistent
with preceding studies based on immunological experiments.
Conclusions: Our method achieved high performance in testing with benchmark datasets. In addition, our study
identified a number of candidates of promiscuous CTL epitopes consistent with previously reported immunological
experiments. We speculate that our techniques may be useful in the development of new vaccines. The R
implementation of EpicCapo+REF is available at http://pirun.ku.ac.th/~fsciiok/EpicCapoREF.zip. Datasets are available
at http://pirun.ku.ac.th/~fsciiok/Datasets.zip.* Correspondence: thammakorn.kmutt@gmail.com
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Cytotoxic T lymphocytes (CTLs) play an important role
in the vertebrate immune system. CTLs recognize
pathogens via peptide presentation on major histocom-
patibility complex molecules (MHCs). If the source of
peptides is an infectious virus, the CTL response could
be stimulated, thus leading to the elimination of virus-
infected cells [1]. MHC-bound peptides are called epi-
topes, and they are usually composed of 8–20 amino acids.
Epitope identification is an essential step toward synthetic
vaccine development, since epitopes play an important
role in the activation of the immune response [2]. Epitopes
are traditionally identified by synthesizing a large number
of nonapeptides and subsequently performing affinity
assays. Those peptides with high affinity for MHC proteins
are considered as potential epitopes. However, the process
of developing a new vaccine is time-consuming and la-
borious when performed with traditional methods. To
avoid the problems of such bottlenecks, instead computa-
tional methods can be effectively applied to search for can-
didate peptides and identify new promising epitopes.
Due to the importance of vaccines for human, we focus
on MHCs in humans, which are referred to as the human
leukocyte antigens (HLAs). There are three classes of
HLAs: I, II, and III. Epitopes presented on HLA class I
molecules are recognized by CTLs. HLA class I proteins
can be categorized into three types according to their
genes: HLA-A, HLA-B, and HLA-C. A majority of previ-
ous studies have focused on the HLA-A*02:01 allele be-
cause it is the most frequent allele of the A2 supertype in
the Northeast Asian and Caucasian populations [3]. Typic-
ally, the HLA-A*02:01 epitope consists of 8–10 amino
acids, and many studies have focused on nonapeptides in
particular: that is, epitopes that are 9 residues long [4-6].
Figure 1A shows the nonapeptide epitope LLFGYPVYV fit-
ted inside the HLA-A*02:01 binding cleft, which consists
of two α-helices and one β-sheet (from PDB entry 1DUZFigure 1 Visualization of the HLA-nonapeptide complex. (A) Crystal str
crystal diffraction (PDB entry 1DUZ [7]) (B) Conformation of the nonapeptid[7]). Figure 1B shows the conformation of the nonapeptide
epitope LLFGYPVYV.
Early epitope binding prediction algorithms were based
on allele-specific motifs [8,9]. For example, for the HLA-
A*02:01 allele, positions 2 and 9 of nonapeptides were the
most important ones for binding. The residues at both
positions were defined as classical anchor residues typic-
ally occupied by leucine, valine, and isoleucine since the
MHC molecule forms hydrophobic sites for amino acids
at these two positions [10]. Additionally, the residues at
positions 1, 3, and 7 were identified as secondary anchor
residues. Positions 1 and 3 were mainly preferred by tyro-
sine and phenylalanine [11,12]. The residue at position 7
was suggested to be an amphipathic residue suitable for
amino acids with small hydrophobic side-chains such as
valine and alanine [13]. In this manner, unknown peptides
that matched with such allele-specific motifs were deter-
mined to be epitopes.
As more data became available, statistical methods
could be applied to calculating a positional scoring matrix.
In the matrix, an element was defined individually for each
position and specific amino acids, resulting in an L × 20
coefficient matrix where L is the length of the peptide. In
general, the matrix is used under the assumption that each
amino acid in a peptide sequence independently contri-
butes to a certain binding energy according to an element
included in the positional scoring matrix. Overall binding
energy is estimated from the summation of binding ener-
gies from all positions. There are several methods based
on such a positional scoring matrix: for example, BIMAS
[14], RANKPEP [15], Gibbs sampler [16], ARB [17], SMM
[18], and SMMPMBEC [19].
Currently, the most successful approach for epitope pre-
diction utilizes machine learning algorithms. These algo-
rithms require large enough datasets for training in order
to obtain reliable results. Fortunately, the Immune Epitope
Database (IEDB) [20] provides more than 100,000 MHCucture of the LLFGYPVYV-HLA-A*02:01 complex resolved by X-ray
e extracted from the complex.
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pathogens, experimental pathogens, and self-antigens
(autoantigens). IEDB encompasses patent data from bio-
technological and pharmaceutical companies, as well as
direct submissions from research programs and partners.
As reliable experimental data are provided, the volume
promises a sufficient grounding for developing good pre-
dictive models. Although IEDB is not the only database
that provides such information, it has more entries than
other existing databases. Examples of other databases are
SYFPEITHI [21], FIMM [22], MHCPEP [23], MHCBN
[24], and AntiJen [25]. NetMHC [26], a predictor based on
artificial neural networks, used data from both IEDB and
SYFPEITHI and performed very well. SVRMHC [27], a
predictor based on support vector regression (SVR) used
data from AntiJen and used LIBSVM [28] for SVR-related
implementation. Moreover, there also exists an epitope
predictor based on a hidden Markov model [29].
The allele-specific motif method, the positional scoring
matrix method, and machine learning-based methods
use only sequence information in general. Almost none
of these methods can provide a clear explanation about
the effects of the physicochemical properties of amino
acids on binding affinity. In some cases, there are not
enough peptides for training: e.g., when using data from
rare alleles. Therefore, three-dimensional (3D) structure-
based methods have been developed [30-32] to uncover
binding mechanisms and address all forces related to
binding affinity. However, such methods are currently
less reliable than data-driven methods [33]. The reason
is that 3D structure-based methods usually require a
number of crystal structures of MHC-peptide com-
plexes, which are still not available in large numbers.
Currently, more than 2,000 HLA alleles have been iden-
tified. Searching for epitopes that bind to a large number
of those alleles would be computationally exhaustive and
time-consuming. Therefore, the concept of allele super-
types was developed by clustering alleles into groups based
on overlapping epitopes [34-38]. Within each supertype,
most of the alleles should share the same epitopes. These
epitopes are called ‘promiscuous epitopes’, which show
great promise for vaccine development due to their poten-
tial for a high level of population coverage.
In this study, we have developed a novel epitope pre-
diction method named EpicCapo. Peptides were encoded
numerically by combining information on the peptide-Table 1 Amino acid descriptors acknowledged in this study
Descriptor Type Technique use
DPPS physicochemical principal compo
FASGAI physicochemical factor analysis (
z-scale physicochemical PCA and partial
ISA/ECI quantum-chemical -MHC (pMHC) contact sites with amino acid pairwise
contact potentials (AAPPs), accompanied by a support
vector machine (SVM) [39]. Our method’s performance
was evaluated by using benchmark datasets and then
compared with other high performance methods. In
addition, identification of candidates of promiscuous
CTL epitopes for influenza A viruses was demonstrated
using the proposed method.
The H1N1 or H5N1 strain of influenza A virus caused
a lethal flu in humans, as seen in the epidemics of
2005–2009. Although inactivated influenza vaccination
is beneficial, the development of more effective vaccines
is still needed, particularly in elderly adults who are
more susceptible to viral infections [40]. Identification of
promiscuous CTL epitopes might aid this issue by pro-
viding candidate peptides from viral proteins for vaccine
development.
Results and discussion
Comparison of peptide-encoding schemes
We compared our peptide-encoding scheme (Section Pep-
tide data encoding) with binary peptide-encoding and with
four amino acid descriptors (Table 1). The results of the
comparison of the peptide-encoding schemes (Table 2)
showed that EpicCapo performed better than others in the
classification tasks. It achieved the highest average area
under the curve (AUC; 0.882), followed by binary encod-
ing (0.879), DPPS (0.878), FASGAI (0.874), z-scale (0.858),
and ISA/ECI (0.796) schemes. All of standard deviations
were less than 0.01. A comparison of receiver operating
characteristic (ROC) curves is shown in Figure 2.
Although EpicCapo used the largest number of features
(M ×K = 360)—higher than binary encoding (180), DPPS
(90), FASGAI (54), z-scale (45), and ISA/ECI (18)—we con-
firmed that its high performance was not due to a larger
number of features. In our study, the training dataset was
separated into 40 datasets corresponding to 40 AAPPs.
Each dataset consisted of 9 features. The classification func-
tions were fitted to these datasets, and after that the AAPPs
were ranked by AUC. The results, as shown in Table 2, sug-
gested that even by using only three top-ranked AAPPs (27
features in total), the classification performance values are
comparable to those obtained by using all AAPPs. These
three top-ranked AAPPs were MICC010101, SIMK990101,
and SIMK990105 (see Additional file 1). They have been
previously used in identifying native-like protein structuresd # of vector Reference
nent analysis (PCA) 10 [4]
FA) 6 [41]
least square (PLS) 5 [42]
2 [43]
Table 2 Classification result of peptide-encoding schemes
Method # of
features
10-fold cross validation on training dataset only Holdout method using training dataset
and testing dataset
sens spec F1 ACC AUC sens spec F1 ACC AUC
EpicCapo 360 0.883 ± 0.005 0.792 ± 0.006 0.886 ± 0.003 0.841 ± 0.004 0.915 ± 0.001 0.883 0.744 0.831 0.815 0.882
EpicCapo(3 AAPPs*) 27 0.876 ± 0.005 0.821 ± 0.005 0.862 ± 0.003 0.848 ± 0.003 0.916 ± 0.001 0.855 0.777 0.828 0.817 0.878
DPPS 90 0.865 ± 0.005 0.760 ± 0.007 0.834 ± 0.004 0.816 ± 0.004 0.888 ± 0.001 0.868 0.697 0.807 0.785 0.878
FASGAI 54 0.847 ± 0.004 0.761 ± 0.004 0.825 ± 0.003 0.801 ± 0.003 0.882 ± 0.001 0.840 0.730 0.803 0.787 0.874
z-scale 45 0.847 ± 0.005 0.732 ± 0.005 0.815 ± 0.004 0.793 ± 0.004 0.873 ± 0.002 0.848 0.676 0.788 0.765 0.858
ISA/ECI 18 0.799 ± 0.005 0.652 ± 0.005 0.760 ± 0.003 0.731 ± 0.003 0.797 ± 0.001 0.829 0.643 0.766 0.739 0.796
Binary encoding 180 0.883 ± 0.005 0.721 ± 0.006 0.831 ± 0.003 0.807 ± 0.003 0.883 ± 0.002 0.887 0.705 0.820 0.799 0.879
Means and standard deviations were calculated by 20 iterations of 10-fold cross validation.
Underlined values represent the highest performance.
sens = sensitivity; spec = specificity; F1 = F-score; ACC = accuracy; AUC = area under the curve.
*These three top-ranked AAPPs were MICC010101, SIMK990101, and SIMK990105 (see Additional file 1).
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accompanying experiments.
Classification results of benchmark datasets
We applied EpicCapo to benchmark datasets of 34 MHC-I
alleles [46]. As shown in Table 3, NetMHC performed the
best, ahead of ARB, SMM, and SMMPMBEC. For EpicCapo,
average AUCs were lower than in NetMHC (0.1%–3.4%) in
13 allele datasets and were higher than in NetMHC (0.1%–
9.3%) in 21 allele datasets when using all of the 40 AAPPsFigure 2 ROC curves of peptide-encoding schemes evaluated on a te(360 features). Almost all of standard deviations were low
except several alleles with results of standard deviation lar-
ger than 0.01. However, if more data are available, these
standard deviations can be decreased. To improve the per-
formance of our method, we developed EpicCapo+ by
selecting an appropriate subset of AAPPs. As seen in
Table 3, the performance of EpicCapo+ was higher than
EpicCapo and comparable with NetMHC. The overall per-
formance of EpicCapo+ is significantly higher than that of
other methods according to a paired t-test (two-tailed)st set.




ARB SMM SMMPMBEC NetMHC EpicCapo EpicCapo+
HLA-A*01:01 1157 0.964 0.980 0.977 0.982 0.972 ± 0.004 0.977 ± 0.003
HLA-A*02:01 3089 0.934 0.952 0.946 0.957 0.950 ± 0.004 0.951 ± 0.004
HLA-A*02:02 1447 0.875 0.899 0.899 0.900 0.901 ± 0.004 0.909 ± 0.004
HLA-A*02:03 1443 0.884 0.916 0.916 0.921 0.920 ± 0.003 0.923 ± 0.003
HLA-A*02:06 1437 0.872 0.914 0.916 0.927 0.925 ± 0.004 0.927 ± 0.004
HLA-A*03:01 2094 0.908 0.940 0.928 0.937 0.934 ± 0.004 0.938 ± 0.003
HLA-A*11:01 1985 0.918 0.948 0.939 0.951 0.945 ± 0.004 0.951 ± 0.002
HLA-A*24:02 197 0.718 0.780 0.801 0.825 0.853 ± 0.012 0.865 ± 0.011
HLA-A*26:01 672 0.907 0.931 0.924 0.956 0.941 ± 0.005 0.957 ± 0.007
HLA-A*29:02 160 0.755 0.911 0.916 0.935 0.944 ± 0.008 0.945 ± 0.010
HLA-A*31:01 1869 0.909 0.930 0.925 0.928 0.930 ± 0.002 0.935 ± 0.003
HLA-A*33:01 1140 0.892 0.925 0.925 0.915 0.926 ± 0.004 0.934 ± 0.004
HLA-A*68:01 1141 0.840 0.885 0.885 0.883 0.891 ± 0.003 0.899 ± 0.003
HLA-A*68:02 1434 0.865 0.898 0.889 0.899 0.901 ± 0.005 0.907 ± 0.003
HLA-B*07:02 1262 0.952 0.964 0.960 0.965 0.960 ± 0.004 0.964 ± 0.002
HLA-B*08:01 708 0.936 0.943 0.956 0.955 0.942 ± 0.005 0.951 ± 0.004
HLA-B*15:01 978 0.900 0.952 0.940 0.941 0.940 ± 0.006 0.950 ± 0.005
HLA-B*18:01 118 0.573 0.853 0.880 0.838 0.886 ± 0.013 0.911 ± 0.009
HLA-B*27:05 969 0.915 0.940 0.941 0.938 0.949 ± 0.005 0.958 ± 0.003
HLA-B*35:01 736 0.851 0.889 0.889 0.875 0.900 ± 0.004 0.907 ± 0.007
HLA-B*40:02 118 0.541 0.842 0.843 0.754 0.811 ± 0.007 0.912 ± 0.011
HLA-B*44:02 119 0.533 0.740 0.739 0.778 0.798 ± 0.009 0.861 ± 0.013
HLA-B*44:03 119 0.461 0.770 0.753 0.763 0.813 ± 0.010 0.871 ± 0.008
HLA-B*51:01 244 0.822 0.868 0.895 0.886 0.930 ± 0.012 0.948 ± 0.015
HLA-B*53:01 254 0.871 0.882 0.885 0.899 0.916 ± 0.008 0.940 ± 0.008
HLA-B*54:01 255 0.847 0.921 0.935 0.903 0.927 ± 0.008 0.938 ± 0.006
HLA-B*57:01 59 0.428 0.871 0.843 0.826 0.792 ± 0.009 0.854 ± 0.010
HLA-B*58:01 988 0.889 0.964 0.945 0.961 0.959 ± 0.005 0.964 ± 0.004
H-2 Db 303 0.865 0.912 0.901 0.933 0.940 ± 0.014 0.968 ± 0.006
H-2 Dd 85 0.696 0.853 0.837 0.925 0.956 ± 0.016 0.985 ± 0.017
H-2 Kb 223 0.792 0.810 0.833 0.850 0.844 ± 0.021 0.880 ± 0.017
H-2 Kd 176 0.798 0.936 0.931 0.939 0.950 ± 0.015 0.966 ± 0.009
H-2 Kk 164 0.758 0.770 0.793 0.790 0.883 ± 0.009 0.926 ± 0.008
H-2 Ld 102 0.551 0.924 0.942 0.977 0.984 ± 0.012 0.992 ± 0.013
Average 0.801 0.895 0.895 0.900 0.912 0.931
t-test|ARB NA 4.37E-5 3.69E-5 1.25E-5 5.21E-6 2.64E-6
t-test|SMM NA 8.61E-1 2.30E-1 8.28E-3 2.87E-5
t-test|SMMPMBEC NA 2.61E-1 3.50E-3 8.49E-6
t-test|NetMHC NA 8.57E-3 7.74E-5
t-test|EpicCapo NA 1.95E-5
For each dataset, AUCs were evaluated based on 5-fold cross validation. In the lower part, p-values of average AUCs were calculated using paired t-tests (two-tailed).
Means and standard deviations were calculated by 20 iterations of 5-fold cross validation for EpicCapo and EpicCapo+.
Underlined values represent the highest performance among ARB, SMM, SMMPMBEC, and NetMHC. Values in bold represent significant improvements of EpicCapo
or EpicCapo+ AUCs from 20 iterations of 5-fold cross validation over the underlined values according to t-tests (one-tailed, significance level = 0.01).
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AAPPs used for estimating the predictive models of Epic-
Capo+ are shown in Additional file 2.
Improved HLA-A-nonapeptide binding predictive models
In this experiment, EpicCapo+ was further developed as
EpicCapo+REF to improve the predictive performance
and identify important positions of nonapeptides in
pMHC binding (Section Improving the performance of
HLA-A-nonapeptide binding predictive models). The IDs
of AAPPs used in EpicCapo+REF are shown in Table 4
(for more details on AAPPs, see Additional file 1). The
most important AAPPs identified by EpicCapo+ were
IDs 14 (MICC010101) and 28 (SIMK990105), which
were selected in 13 out of 14 alleles. IDs 11
(KESO980102) and 26 (SIMK990103) were also consid-
ered to be important, because they were selected in 9
out of 14 alleles. From previous studies that used AAPPs
in MHC I epitope prediction, AAPP IDs 19 (MIYS960102)
and 2 (BETM990101) proved to be important in peptide-
MHC binding predictions [5,47,48]. In our study, however,
BETM990101 was not selected for an AAPP subset for any
allele, and MIYS960102 was chosen for only two alleles
(A*0203 and A*0206). In a report by Schueler-Furman et al.
[47], KESO980102 was also tested and compared with
MIYS960102; however, there was no significant improve-
ment in the predictive performance. Therefore, it is inter-
esting that MICC010101, SIMK990105, KESO980102, and
SIMK990103 were important for generating better predict-
ive models in our study.Table 4 Optimal subsets of AAPPs and number of selected fe
allele datasets
Allele AUC of EpicCapo+REF IDs of AAPP u
A *01:01 0.980 1,11,14,20,24,26
A *02:01 0.958 9,11,14,24,26,28
A *02:02 0.913 14,28
A *02:03 0.925 3,9,11,14,19,24,
A *02:06 0.926 1,3,9,11,13,14,1
A *03:01 0.946 11,14,20,24,26,2
A *11:01 0.956 11,14,26,28
A *24:02 0.877 5,6,14,24,28,31
A *26:01 0.960 14,28
A *29:02 0.955 5,8,9,20,33
A *31:01 0.940 11,14,20,26,28,3
A *33:01 0.940 14,28
A *68:01 0.904 11,14,20,26,28,3
A *68:02 0.913 1,9,11,14,20,22,
Average 0.935We further investigated the generated features according
to the selected subset of AAPPs. In our peptide-encoding
scheme, nine features were generated from one AAPP, cor-
responding to the nine amino acid positions in the nona-
peptide. Previous studies have indicated that not all
positions were important in pMHC binding [4,10-12].
Therefore, some features corresponding to specific positions
could be removed to improve the predictive performance.
The Relief algorithm [49] was employed in our study to
rank the features according to their importance in separat-
ing the nonbinding peptides from the binding ones. The
ranking results showed that the ten top-ranked features
correspond to positions 9 and 2 in most of the alleles, fol-
lowed by positions 3, 1, or 7 (see Additional file 3). As
indicated in Tables 3 and 4, the overall AUC value of Epic-
Capo+REF was higher than that of EpicCapo+; however, it
was still slightly lower than that of NetMHC in the
A*01:01 and A*02:06 alleles. In summary, EpicCapo+REF
performed better than other methods, with an average
AUC of 0.935. Table 4 also shows the number of selected
features after employing the Relief-F algorithm. These
numbers were different for specific alleles. For the
A*01:01, A*02:02, and A*06:01 alleles, no features were
removed. However, for the A*02:06, A*24:02, A*29:02, and
A*68:02 alleles, 20 or more features were removed. Inter-
estingly, features corresponding to positions 5 and 8,
which have previously been considered to not significantly
contribute to HLA binding potentials, were still included
in some of the selected feature subsets. Therefore, we
assumed that features corresponding to different positions
are not independent, and that all features from allatures identified by EpicCapo+REF using 14 HLA-A
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with the highest-performance (see Additional file 3).
Candidates of promiscuous epitopes for a development
of influenza A viral vaccines
Since EpicCapo+REF performed better than the other
existing methods when testing with 14 HLA-A allele
datasets, it was further used to find candidates of pro-
miscuous epitopes from influenza A viral sequences. Epi-
topes from protein sequences of H1N1 (A/PR/8/34),
H3N2 (A/Aichi/2/68), H1N1 (A/New York/4290/2009),
and H5N1 (A/Hong Kong/483/97) were identified using
EpicCapo+REF. The prediction results of all influenza A
strains categorized into specific alleles are shown in
Table 5. All 14 alleles were assigned to supertype groups
using the supertype classification defined by previous
studies [34-37]. The A*01:01 and A*26:01 alleles were
assigned to the A1 group. The A*29:02 allele was
assigned to an unidentified group. As shown in Table 5,
there are a small number of predicted positive peptides
in the A1 supertype. For example, in case of H1N1
(A/PR/8/34), only one peptide was identified as positive
for the allele A*26:01. In contrast, there were quite high
numbers of predicted positive peptides in the A2, A24,
and A3 supertypes. Even the A*29:02 allele, which was
assigned to an unidentified group, had a higher number
of predicted positive peptides than those in the A1
group. Based on our findings, when promiscuous epitopes
were identified from the overlapping epitopes of four In-
fluenza A viral strains (Additional file 4), the A1 group
rarely shared peptides with other groups. As shown inTable 5 Prediction results of EpicCapo+REF using four influenz
Allele # of predicted po
H1N1 New York/4290/2009 H5N1 Hong Kong/4
A *01:01 14 13
A *26:01 6 9
A *29:02 103 134
A *02:01 122 160
A *02:02 302 370
A *02:03 268 326
A *02:06 200 250
A *68:02 198 220
A *24:02 90 108
A *03:01 85 94
A *11:01 162 176
A *31:01 183 227
A *33:01 96 117
A *68:01 263 346
Total 2092 2550Additional file 4, the A*01:01 allele shared only one pep-
tide (YSHGTGTGY) with A*29:02, and the A*26:01 allele
shared the peptide DTVNRTHQY with A*29:02 and
A*68:01. Moreover, the A*29:02 allele also shared peptides
with the A2 and A3 groups: e.g., SMELPSFGV and
QTYDWTLNR, respectively (Additional file 4). Therefore,
A*29:02 can be considered as a special group that links
A1, A2, and A3 together. Furthermore, Doytchinova et al.
[38] assigned A*29:02 to the A3 group. However, we did
not find overlapping epitopes from the four Influenza A
viral strains in the A*24:02 allele assigned to the A24
group. This suggested that A*24:02 itself is different from
other alleles considered here, and this might be the reason
why most of the previous studies assigned it separately to
the A24 group [34-37]. As shown in Additional file 4, 51
peptides (67.1%) of the total 76 epitopes were immuno-
logically validated as positive, whereas 9 peptides (11.8%)
were validated as negative. No evidence of immunological
validation could be obtained for 16 peptides (21.1%).
These results indicate that our newly developed method
provides a markedly high accuracy in epitope identifica-
tion, given the fact that most of the identified epitopes
could be correlated with immunological experimental evi-
dence. However, even without such immunological evi-
dence, those epitopes identified by our computational
approach might be considered as candidates for new vac-
cine development.
Our results are in agreement with the study by Uchida
[50], which identified promiscuous epitopes from influ-
enza A H1N1 (A/PR/8/34), H3N2 (A/Aichi/2/68), H1N1
(A/New York/4290/2009), and H5N1 (A/Hong Kong/483/97).a A strains categorized by specific alleles
sitive peptides Super
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the A2 group. In our results, the epitopes identified by
EpicCapo+REF in the A2 group were consistent with them
(Table 6). In addition, we found promising candidates of
promiscuous epitopes also for the A1 and A3 groups as
shown in Additional file 4.
Although the overall performance of EpicCapo+REF
was high, there are two limitations in the use of this
method. The first limitation is the length of input pep-
tides must be equal to 9. In the further study, we will
improve EpicCapo+REF to be applicable to peptides with
the length of 8–11. The second limitation is that input
amino acids must not be special or ambiguous ones.
Examples of special amino acids are U (Selenocysteine)
and O (Pyrrolysine). Also, examples of ambiguous amino
acids are B (Asparagine or aspartic acid), Z (Glutamine
or glutamic acid), and J (Leucine or Isoleucine). Epic-
Capo+REF are not applicable with these amino acids since
they are not included in AAPPs.Conclusions
In this study, we have developed a novel method for epi-
tope prediction. Peptides were encoded numerically, com-
bining information of pMHC contact sites and amino acid
pairwise contact potentials, accompanied by an SVM for
estimating the predictive model. Our method achieved high
performance in testing with benchmark datasets. In
addition, our study identified a number of candidates of
promiscuous CTL epitopes from four influenza A viral
strains, consistent with previously reported immunological
experiments. This consistency in results strongly supports
the accuracy of our method. We speculate that our techni-
ques may be useful in identifying promising candidates of
promiscuous epitopes for the development of new vaccines.Table 6 Comparison of epitopes identified by EpicCapo+REF w
identified by Uchida [50]














We propose a novel peptide-encoding scheme for ma-
chine learning algorithms. This scheme utilized the in-
formation of pMHC contact sites retrieved from the
international ImMunoGeneTics information system,
IMGT [51], the allele-specific positional scoring matrices
developed by SMMPMBEC [19], and the AAPPs from
AAindex [52].
The reference pMHC contact sites retrieved from
IMGT were modified by adding more MHC positions.
The added MHC positions were determined by observ-
ing the pMHC contact sites of the selected 189 crystal
structures of the HLA-nonapeptide complex collected
from IMGT entries specific to the MHC-I receptor type.
If there were new contact positions, the reference
pMHC contact sites were modified by adding those new
positions. Therefore, more HLA-nonapeptide contact
positions were included in the modified pMHC contact
site because the reference pMHC contact sites resulted
from the use of only 74 crystal structures of the HLA-
nonapeptide complex [51]. Utilizing the modified pMHC
contact sites should provide more reliable results during
the prediction. Additional file 5 shows the references
and added pMHC contact sites positions. This informa-
tion served as a binding template between the peptide
and MHC. In NetMHCpan [53], the reference pMHC
contact sites were used to extract a pseudosequence
representing the given MHC molecule. When perform-
ing prediction, sequence information from both peptide
and MHC was taken into account. However, the pairs of
amino acids between the MHC molecule and peptide
were not of concern. Therefore, to generate a more in-
formative predictive model, we used information about
the pairs of amino acids at the interface between anith the broadly protective influenza A viral epitopes
by [50] Shared alleles identified by EpicCapo+REF
A*02:01, A*02:02, A*02:03, A*02:06
A*02:01, A*02:02, A*02:03, A*02:06, A*68:02
A*02:01, A*02:02, A*02:03, A*02:06
A*02:01, A*02:02, A*02:03, A*02:06
A*02:01, A*02:02, A*02:03, A*02:06
A*02:01, A*02:02, A*02:03, A*02:06
A*02:01, A*02:02, A*02:03, A*02:06
A*02:01, A*02:02, A*02:06, A*68:02
A*02:01, A*02:02, A*02:03, A*02:06
A*02:01, A*02:02, A*02:03, A*02:06
A*02:01, A*02:02, A*02:03, A*02:06, A*68:02
A*02:01, A*02:02, A*02:03, A*02:06
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http://www.biomedcentral.com/1471-2105/13/313MHC molecule and a nonapeptide, represented by
AAPPs. In addition, the allele-specific positional scoring
matrices developed by SMMPMBEC were used in our
study. These matrices provide information of how likely
a given amino acid would be preferred or avoided in a
specific residue. Like NetMHCpan, SMMPMBEC did not
use AAPPs. Consequently, we proved that a proper se-
lection of AAPPs could lead to higher performance in
the prediction. The encoded data could be further used
in tasks of classification or regression using machine
learning algorithms. In this study, we demonstrated the
feasibility of the classification task by using the SVM
implemented in the R package kernlab [39].
Here, we propose a novel scheme for encoding nonapep-
tides into input vectors of the SVM. Suppose E(a1,a2) is an
AAPP for the amino acids a1 and a2. If two or more types of
AAPPs are available, we denote kth type of the AAPP by Ek
(a1,a2). Also, we denote the ith amino acid of the nonapep-
tide n and the jth amino acid of HLA by ui
(n) and vj, respect-
ively. In order to combine information of position-specific
amino acid scores of the nonapeptides with AAPPs, we de-
fine a score Sk,i
(n) for the ith a kth type of AAPP as follows:















where L is the length of the HLA protein, Ti(a) is the ith
position score of the amino acid a for the nonapeptides
described by SMMPMBEC, and δij is an indicator variable
that takes the value of 1 if the ith amino acid of a nona-
peptide and the jth amino acid of HLA contact each other,Figure 3 Our peptide data-encoding scheme, using the first positionand 0 otherwise. Here, the positional scoring matrix Ti(a)
is trained based on training data and multiplied by −1 to
reverse the order of values (a high positive value denotes
high preference between an amino acid and the position)
and scaled into the range of 1 to 10 since we need to avoid
loss of information when Ti(a) equals zero. In fact, any
range that does not include zero can be used; in this study,
it is the range of 1 to 10. The scaling of positional scoring




is the number of contact sites for the ith amino acid of a
nonapeptide (see Additional file 5). Intuitively, this score
represents average pair-potential of contact sites, weighted
by position-specific amino acid score for nonapeptides.
Let K be the number of AAPPs available, and M be the
length of the peptide, set to 9 throughout this study. Using
this scoring scheme, we transform a nonapeptide n into a
M ×K-dimensional numerical vector, whose (M(k–1) + i)th
element is Sk,i
(n). For example, the encoded nonapeptides
consist of 9 features if one AAPP is used, and 360 features
if 40 AAPPs are used. Figure 3 illustrates an example of
the data-encoding scheme for the first position of the
nonapeptide.
Our peptide-encoding scheme was compared with binary
peptide-encoding and with four amino acid descriptors, as
shown in Table 1 using the dataset reported by Bi and col-
leagues (supplementary information for Table S2 in [54]).
This dataset consists of 1,998 quantitative affinity-known
HLA-A*02:01-restricted nonapeptides. The dataset was ran-
domly partitioned into a training set containing 1,500 nona-
peptides for estimating predictive models using the SVM,
and a test set containing 498 nonapeptides for validatingof a nonapeptide as an example.
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http://www.biomedcentral.com/1471-2105/13/313the models. For our peptide-encoding scheme, the pos-
itional scoring matrix was trained based on the external
dataset downloaded from IEDB, consisting of 500 nonapep-
tides restricted to the HLA-A*02:01 allele (Additional file 7).
These nonapeptides were included in neither training nor
test sets. For the binary peptide-encoding, each amino acid
was encoded as a binary vector of length 20, resulting in a
vector of length 180 for a nonapeptide. In case of using
amino acid descriptors, the length of an encoded vector
would be equal to M times larger than the length of de-
scriptor vectors. The performances of the data-encoding
schemes were evaluated in classification tasks, using a 10-
fold cross validation. Throughout our experiments, the
parameter C (cost of constraint violation), epsilon, and the
type of kernel used for the SVM were 1, 0.1, and the radial
basis kernel, respectively. The class for each nonapeptide
was determined by using an IC50 affinity cutoff at 500 nM.
Nonapeptides with an affinity less than 500 nM were con-
sidered to be binders, and non-binders otherwise. The
study by Moutaftsi et al. [55] showed that 90 of epitopes
that could stimulate CD8+ T cell responses bound to
MHC with affinities lower than 500 nM. The predictive
performance is evaluated using five measures: overall ac-
curacy (ACC), sensitivity (sens), specificity (spec), F-score
(F1), and area under the curve (AUC) for the received op-
erating characteristic curve. ACC, sens, spec, and F1 are
defined as
ACC ¼ TPþ TN






2TPð ÞþFNþ FPð Þ ;
where TP, FP, TN, and FN are the numbers of overall true
positives, false positives, true negatives, and false nega-
tives, respectively.
Validation of predictive models using benchmark datasets
The performance of EpicCapo was validated by using
benchmark datasets of 34 MHC-I alleles provided by
Peters et al. [46]. In this experiment, the positional scoring
matrices were trained based on training data according to
the cross validation technique. 20 iterations of 5-fold cross
validation were conducted to evaluate AUCs for EpicCapo.
We compared the results of our method with those of
ARB, NetMHC, SMM, and SMMPMBEC.EpicCapo was further developed as EpicCapo+ by
selecting AAPPs. Each encoded allele dataset was ini-
tially separated into 40 datasets according to the 40
AAPPs. The classification task was performed for each
dataset to calculate AUC using the SVM and using the
same parameters as EpicCapo. Then, the 40 datasets
were ranked by AUC from highest to lowest. Next, the
classification task was performed again by adding the
datasets of AAPPs one by one based on their rank.
Finally, the optimal subset of AAPPs that led to the
highest AUC was identified for each allele. The average
AUCs of all alleles as calculated from EpicCapo+ were
compared with those from EpicCapo and other methods
using paired t-tests (two-tailed). For each allele, the
AUCs from 20 iterations of 5-fold cross validation of
EpicCapo and EpicCapo+ were compared with the max-
imum AUC among other methods by using t-tests (one-
tailed, significance level = 0.01).
Improving the performance of HLA-A-nonapeptide
binding predictive models
To increase the performance of our predictive models, the
positional scoring matrices used in this experiment were
trained based on datasets containing larger number of
nonapeptides. These matrices are available at [56]. After
encoding 14 HLA-A allele datasets using the downloaded
matrices, EpicCapo+ was performed again to identify opti-
mal subsets of AAPPs therein. We used the Relief-F algo-
rithm [49] implemented in the machine learning software
Weka [57] to perform the feature selection task, ranking
the features according to their importance in discriminat-
ing the MHC binder peptides from the non-binder ones.
The default parameters provided by Weka were used, and
a 5-fold cross validation was conducted for evaluating
feature importance. The best feature subsets were con-
structed by adding the features, one by one, from the top-
ranked feature to the last one in the classification task
using the SVM. The AUC gradually increased with the
addition of features, until it reached the highest value. Fea-
tures after this point were considered irrelevant and
ignored. We named this method, accompanied with the
Relief-F algorithm, EpicCapo+REF.
Identification of candidates of promiscuous epitopes
EpicCapo+REF was further tested to identify candidates of
promiscuous epitopes—i.e., nonapeptides that were pre-
dicted to be MHC binders for various HLA alleles—from
the protein sequences of four influenza A viral subtypes:
H1N1 (A/PR/8/34), H3N2 (A/Aichi/2/68), H1N1 (A/New
York/4290/2009), and H5N1 (A/Hong Kong/483/97).
These protein sequences were downloaded from the NCBI
website (http://www.ncbi.nlm.nih.gov/). The nonapeptides
were generated from these sequences by using a nonamer
sliding window. Next, all of the generated nonapeptides
Saethang et al. BMC Bioinformatics 2012, 13:313 Page 11 of 12
http://www.biomedcentral.com/1471-2105/13/313were used as inputs in EpicCapo+REF predictive models.
These models were estimated by using 14 HLA-A allele
datasets, and each model was specific for each allele type.
The identified epitopes were validated by cross-checking
with the results of immunological experiments.
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